Two-Pronged attack on rare blood cancer aims to control disease and bank stem cells
NCT ID NCT00492050
Summary
This study tested a combination of two drugs, bortezomib and rituximab, as an initial treatment for Waldenstrom's macroglobulinemia, a rare blood cancer. The goal was to see if this approach could control the disease and also successfully collect patients' own stem cells. These stem cells could be stored for a potential future transplant if the cancer worsened, offering a backup treatment option.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM'S MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.